Cat. No.: DAB-0012048
Product Information | |
---|---|
Clonality | Polyclonal |
Host Species | Rabbit |
Reactivity | Human, Mouse, Rat |
Applications | WB |
Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human Gab2 protein. Antibodies are purified by peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | GAB2 |
UniProt No. | Q9UQC2 |
Gene ID | 9846 |
Gene Description | GRB2-associated-binding protein 2 belongs to the Gab family of signaling scaffolds, which are characterized by a highly conserved N-terminal PH domain for membrane recruitment, multiple proline-rich motifs for the recruitment of SH3 domain-containing proteins, such as GRB2, and multiple tyrosine residues capable of associating with SH2 domain-containing proteins, such as p85 PI3K, CrkL, and SHP-2, in a phosphorylation-dependent manner. Research studies have shown that Gab2 is a widely expressed protein that participates in orchestrating signals downstream of many transmembrane receptors for growth factors and cytokines. Indeed, Gab2 was initially identified as a tyrosine-phosphorylated protein associated with SHP-2 and the p85 subunit of PI3K in response to engagement of the IL-3 and M-CSF receptors. Subsequent studies also identified Gab2 as a participant in signaling cascades triggered by the T cell antigen receptor. It is now well established that Gab2 is a critical component of signaling cascades triggered by numerous oncogenic tyrosine kinases. In the context of human disease, Gab2 has been shown to be overexpressed in breast cancer and ovarian cancer, which facilitates tumor cell proliferation and survival. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.